Meta-analysis of six-month memantine trials in Alzheimer’s disease

[1]  D. Knopman.  Commentary on “Meta-analysis of six-month memantine trials in Alzheimer’s disease.” Memantine has negligible benefits in mild to moderate Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[2]  L. Schneider.  Commentary on “Meta-analysis of six-month memantine trials in Alzheimer’s disease.” Wuthering forest plots: Distinguishing the forest from the plots , 2007, Alzheimer's & Dementia.

[3]  Steven G Potkin,et al.  Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[4]  D. Bennett,et al.  Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease , 2005, Journal of the International Neuropsychological Society.

[5]  A. Enz,et al.  Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain , 2004, Neuropharmacology.

[6]  J. Shua-haim,et al.  P1-374 Safety, torebality, and caregiver's impressions of combination therapy with donepezil and memantine for the treatment of Alzheimer's disease , 2004, Neurobiology of Aging.

[7]  Sameer Patel,et al.  P1-377 Safety, tolerability, and caregiver's impressions of combination therapy with rivastigmine and memantine for the treatment of Alzheimer's disease , 2004, Neurobiology of Aging.

[8]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[9]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[10]  S. Hartmann,et al.  Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy , 2003, International clinical psychopharmacology.

[11]  Anirvan Ghosh.  Learning More About NMDA Receptor Regulation , 2002, Science.

[12]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[13]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[14]  W. Danysz,et al.  No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. , 2000, Life sciences.

[15]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[16]  B. Winblad,et al.  Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.

[17]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[18]  Peter Langhorne,et al.  Integrating Heterogeneous Pieces of Evidence in Systematic Reviews , 1997, Annals of Internal Medicine.

[19]  F. Boller,et al.  Assessment of the severely impaired patient: Description and validation of a new neuropsychological test battery. , 1990 .

[20]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[21]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[22]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[23]  M. Riepe,et al.  Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study. , 2006, Primary care companion to the Journal of clinical psychiatry.

[24]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[25]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[26]  B. Reisberg.  Functional assessment staging (FAST). , 1988, Psychopharmacology bulletin.

[27]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.